Table 4.
Treatment-emergent adverse events
| Adverse eventa | Oral contraceptive (n =19) | Oral contraceptive plus placebo (n =19) | Oral contraceptive plus ziprasidone (n =19) |
|---|---|---|---|
| Subjects with adverse events | 5 | 11 | 18 |
| Adverse events | 5 | 16 | 47 |
| Subjects discontinued due to adverse events | 0 | 0 | 1 |
| Asthenia | 0 | 1 | 13 |
| Somnolence | 0 | 0 | 6 |
| Headache | 3 | 6 | 3 |
| Nausea | 0 | 0 | 3 |
| Agitation | 0 | 0 | 3 |
| Insomnia | 0 | 0 | 3 |
| Myalgia | 0 | 2 | 2 |
| Abnormal dreams | 0 | 0 | 2 |
| Otherb | 2 | 7 | 12 |
a
Subjects with multiple occurrences of the same adverse event were counted once only.
b
Includes all other treatment-emergent adverse events, none of which occurred in more than one subject in any treatment group.